

Formulation and *In vitro* Characterization of Hydrochlorothiazide Gastroretentive Floating Drug Delivery System

Md. Asif Hasan¹, Sabiha Sultana², Sujan Banik¹, Md. Masud Kaisar Bhuiyan¹,
Md. Selim Reza³ and Mohammad Salim Hossain¹

¹Department of Pharmacy, Noakhali Science and Technology University, Sonapur, Noakhali-3814, Bangladesh

²Department of Pharmacy, University of Asia Pacific, Dhaka-1207, Bangladesh

³Department of Pharmaceutical Technology, University of Dhaka, Bangladesh

Received: November 24, 2014; Accepted: January 17, 2016; Published (web): January 31, 2016

ABSTRACT: The purpose of the study was to develop and optimize floating bioadhesive gastroretentive drug delivery system (GRDDS) exhibiting a unique combination of floatation and bioadhesion to prolong residence in the stomach, using hydrochlorothiazide (HCTZ) as a model drug. Formulated matrix tablets were prepared by direct compression method with two different rate controlling polymer HPMC K4M and Carbopol 971. The formulated tablets were evaluated for physical characterization, floating lag time, swelling index and drug content uniformity. The drug release study was carried out in 0.1N HCl as the medium (pH 1.2) for 8 hours using USP type II dissolution apparatus and investigated the effects of polymers on the drug release profile. *In vitro* buoyancy study results found to be 10–33 sec and >8 h, floating lag time and total floating time respectively. Simulated drug release pattern in different kinetic models of Korsmeyer-Peppas release suggests that the mechanism controlling of the drug release from all formulations was the anomalous non-Fickian or anomalous release. Polymer with lower viscosity (HPMC K4M) was found to be beneficial than higher viscosity polymer (Carbopol 971) in improving the release properties of gastric floating drug delivery system. Incorporation of Carbopol in formulation also helped in maintaining buoyancy of system with desirable drug release. Further study is necessary in case of *in vitro- in vivo* relationship, but this study will ready to lend a hand to future scientists working in this field to successfully exploit the potential of this drug delivery system for the advantage of mankind.

Key words: Hydrochlorothiazide, HPMC K4M, Carbopol 971, GRDDS

INTRODUCTION

Various types of oral controlled release formulation have been developed to improve the clinical efficacy of drugs having short half-lives as well as to increase patient compliance. These formulations are designed to deliver drugs at a predetermined rate over a wide range of conditions and durations of therapeutic treatments. Over the last three decades, a variety of approaches have been pursued to increase the retention of an oral dosage form in the stomach, like floating drug delivery system (FDDS)¹ expanding and swelling systems²

high density system³ modified shape system⁴ bioadhesive system⁵ and other delayed gastric emptying device.⁶ Detailed studies on controlled drug delivery system reported that, FDDS is a gastroretentive dosage form (GRDF), which is considerably easy and reasonable approach to prolong the gastric residence time (GRT) in extending an optimum drug bioavailability.⁷ Effervescent FDDS and non-effervescent FDDS, two different technologies are attempted to release drug in case of floating drug delivery system based on mechanisms. In case of effervescent system, when the drug reaches in stomach CO₂ is liberated by the acidity of gastric substance and is entrapped in jellified hydro colloid. This liberated gas, if expelled

Correspondence to: Mohammad Salim Hossain
Cell: +88-01711-200410
Email: pharماساليم@yahoo.com

Drug content and evaluation of physical characterization. The drug content of the formulated tablets of each formulation was estimated using 0.1M sodium hydroxide and the sample was analyzed by using a double beam UV-Visible spectrophotometer (UV-1800 Shimadzu) at 272 nm. The formulated tablets were evaluated for thickness, hardness, friability, weight variation with regards their British Pharmacopeia specification.¹¹

***In vitro* buoyancy study.** The time required for dosage form to emerge of medium called buoyancy lag time (BLT) or floating lag time (FLT). Duration of time by which the dosage forms constantly emerges on surface of a medium called total floating time (TFT). The prepared tablets were subjected to *in vitro* buoyancy test by placing them in 100 mL glass beaker containing 0.1N HCl (pH 1.2, temp. $37 \pm 0.5^\circ$ C) as per USP. The time required for the tablet to rise to the surface and float was determined at floating lag time and the time for which a tablet constantly floats on the surface of the medium was calculated for the determination of total floating time.¹²

Swelling index. Swelling of tablet excipients particles involves the incorporation of a liquid resulting in an increase in weight and volume. Liquid uptake by the particle may be owing to saturation of capillary spaces inside the particles or hydration of macromolecule. The liquid passed the particles through pores and bound to large molecule; breaking the hydrogen bond and resulting in the swelling of particle. Weight gain by the tablet is a technique used for measuring the extent of swelling. For determination of swelling index, each tablet from all formulations pre-weighed and placed in a beaker containing 100 ml of 0.1N HCl at room temperature. After each hour the tablet was removed from beaker and weighed again up to 5 hours.¹³ The swelling index was then calculated using the formula:

$$\text{Swelling Index} = \frac{(W_t - W_0)}{W_0} \times 100$$

where, W_t = weight of tablet at time t; W_0 = initial weight of tablet.

***In vitro* drug release studies.** The *in-vitro* release of HCTZ from the formulated tablets was carried out in USP type II apparatus using 900 mL of dissolution medium maintained at $37.0 \pm 0.5^\circ$ C and a stirring rate of 75 rpm. Triplicate basket system was considered for dissolution studies using 900 mL of 0.1N HCl (pH 1.2) as a dissolution medium for the following 8 hours. At specific time interval aliquots of 10 mL was withdrawn for measuring the drug release and in every case 10 mL of fresh dissolution medium was substituted to maintain the volume constant. After filtration, the amount of Hydrochlorothiazide in each sample was determined spectrophotometrically at 272 nm.⁶

Analysis of release data. The release data obtained were treated according to zero-order (cumulative amount of drug release versus time (hr)), first order (log cumulative percentage of drug remaining versus time (hr)), Higuchi (cumulative percentage of drug release versus square root of time (hr)), Korsmeyer-Peppas (log cumulative percentage of drug release versus log time (hr)) equation models. Korsmeyer-Peppas *et al.*¹⁴ has introduced a well-known exponential equation, which is often used to narrate the drug release behavior form polymeric systems. This equation was applied in this study to analyze the resulting dissolution data.

$$M_t / M_\infty = k t^n$$

where, M_t is the amount of drug release at time t, M_∞ is the amount of drug release after infinite time; k is a release rate constant incorporating structural and geometric characteristics of the tablet and n is the diffusional exponent indicative of the mechanism of drug release. A value of n = 0.45 indicates Fickian (case I) release, > 0.45 but < 0.89 for non-Fickian (anomalous) release and > 0.89 indicates super case II type of release. Cass II normally indicates the erosion of the polymeric chain and anomalous transport (non-Fickian) is a combination of both diffusion and erosion controlled-drug release.¹⁵

Mean dissolution time (MDT) was calculated from dissolution data using the following equation (Mockel and Lippold).¹⁶

$$\text{MDT} = (n / n+1) k^{-1/n}$$

where, n is the release exponent and k is the release rate constant.

RESULTS AND DISCUSSION

Physical characterization and drug content of floating tablets. The prepared tablets were subjected to preliminary characterization such as physical parameters (thickness, diameter, hardness and friability) and weight uniformity of all the fabricated tablets. The values are presented in Table 2. Table 2 also shows the drug content of these tablets. All the batches showed uniform thickness and diameter. The

percentage of average weight deviation of 10 tablets of each formulation was less than (5%), and hence all formulations passed the test for uniformity of weight as per official requirements. The hardness of the tablets of all the formulations ranged from 4.75 ± 0.16 to 6.43 ± 0.11 kgf showed an acceptable range of limit. In this study, the percentage friability for all the formulations was below 1% w/w, indicating that the friability is within the prescribed limits. The prescribed drug content of all the formulations showed good uniformity and this range of drug content among different batches showed from 97.30% to 99.78%.

Table 2. Tablet properties of the different formulations of HCTZ floating tablets.

Batch code	Parameters		
	Diameter (mm) (n=3)	Friability (%)	Drug content (%)
F-1	13	0.09	99.15
F-2	13	0.21	98.45
F-3	13	0.35	98.60
F-4	13	0.34	98.45
F-5	13	0.27	99.78
F-6	13	0.31	97.45
F-7	13	0.28	98.47
F-8	13	0.18	97.30
F-9	13	0.08	99.40
F-10	13	0.22	99.21
F-11	13	0.41	99.65
F-12	13	0.26	97.40

Table 3. *In vitro* buoyancy and swelling index study of formulations F1-F6 containing HPMC K4M.

Batch code	Floating lag time (sec)	Swelling index after 5 hr	Total floating time (hr)
F-1	33	82.21%	>6
F-2	20	89.99%	>6
F-3	28	100.75%	>6
F-4	16	113.05%	>6
F-5	21	127.70%	>8
F-6	29	128.43%	>8

Table 4. *In vitro* buoyancy and swelling index study of formulations F7-F12 containing Carbopol.

Batch code	Floating lag time (sec)	Swelling index after 5 hr	Total floating time (hr)
F-7	18	73.23%	>6
F-8	13	81.67%	>6
F-9	22	93.75%	>8
F-10	15	104.05%	>8
F-11	19	115.90%	>8
F-12	10	121.27%	>8

***In vitro* buoyancy and swelling studies.** HPMC and Carbopol was selected as a polymer considering its widespread applicability in controlled release drug formulation and excellent gelling activity in formulations along with safety, effectiveness, cost and availability. Sodium bicarbonate generates CO₂ gas in the presence of HCl acid present in dissolution medium. The generated gas is trapped and confined within the gel, thus decreasing the density of the tablet. When the density of the tablet falls below 1 (density of water), then the tablet becomes buoyant. From the present study it was reported that FLT is elevated for the formulations containing retardant polymer like HPMC K4M and Carbopol 971. Total Floating Time is better when the amount of polymer is gradually increased (Table 3 and Table 4). All formulations showed good buoyancy properties due to their low density than GI fluid. Formulation

containing carbopol 971 (F7-F12) showed good floating behavior than formulation containing HPMC K4M (F1-F6).

Water uptake by the tablets was used as process of swelling of polymers that was determined. The percent swelling of the tablet was determined at the end of 5 hrs (Figure 1) increase in percent swelling was found with increasing concentration of polymers.

Though both formulations containing HPMC K4M and carbopol971 have the same concentration of polymer but HPMC K4M stores more water than carbopol 971. The swelling index was highest for tablets of formulation F6 (128.43%) than in F12 (121.27%). This indicates that HPMC stores more water content in matrix than Carbopol 971.




Figure 1. Photographic images showing water uptake by the tablets.

Release kinetic studies. The dissolution data of all formulations were fitted to various mathematical models such as zero-order, first-order, Higuchi, Korsmeyer and Peppas model to know which mathematical model will best fit for the obtained release profile. The cumulative percentage of drug release after 8 hours of all formulations and the release parameters of all formulations are presented in Table 5. The release profile of promising batch, F6, fitted best to zero order with r^2 value of 0.992 (Figure 2). Based on the 'n' values ranging from 0.45 < n < 0.89 the drug release was found to follow anomalous or non-Fickian release. This numerical value indicates is a coupling process of the diffusion and erosion mechanism and that the process was controlled by more than one process. The finding results of this study was in harmony with other published works.^{17,18}

The dissolution studies of in-vitro of formulations F1 to F12 indicated that as the polymer concentration and viscosity was increased, there was a reduction in the drug release. Formulations containing polymer HPMC K4M (F1 to F6) has higher drug release when compared to formulations having polymer Carbopol 97 (F7 to F12) (Figure 3). The amount of drug release from formulated formulation was found to be in order of $F1 > F2 > F3 > F4 > F5 > F6$ and $F7 > F8 > F9 > F10 > F11 > F12$ in two cases of polymer concentration. Increasing polymer concentration causes decreasing drug release rate of all formulated formulations of floating tablets.

Table 5. Cumulative percentage release (CPR) and release kinetics parameter of formulated floating tablets of HCTZ.

Formulations	CPR*	Zero order	First order	Higuchi	Korsmeyer-Peppas	
		R ²	R ²	R ²	R ²	n
F1	58.67	0.991	0.986	0.949	0.960	0.668
F2	54.23	0.975	0.991	0.981	0.997	0.646
F3	44.84	0.979	0.99	0.967	0.989	0.721
F4	37.38	0.971	0.984	0.969	0.993	0.781
F5	37.32	0.990	0.994	0.958	0.997	0.806
F6	37.23	0.992	0.987	0.934	0.989	0.829
F7	34.80	0.969	0.986	0.988	0.994	0.705
F8	34.17	0.986	0.995	0.987	0.990	0.700
F9	33.80	0.986	0.993	0.971	0.999	0.741
F10	31.40	0.965	0.981	0.969	0.998	0.775
F11	31.09	0.958	0.975	0.989	0.998	0.678
F12	27.61	0.957	0.973	0.987	0.999	0.678

*CPR of drug after 8 hours

Table 6. Required time for 25, 50, 75 percentage of drug release and MDT.

Formulations	T _{25%}	T _{50%}	T _{75%}	MDT (hr)
F1	1.495	2.695	3.895	4.49
F2	1.465	2.723	3.982	4.36
F3	1.799	3.313	4.826	10.36
F4	2.006	3.712	5.419	8.58
F5	2.139	3.938	5.736	12.09
F6	2.208	4.033	5.858	12.49
F7	2.597	4.990	6.128	18.73
F8	2.430	4.662	6.358	16.98
F9	2.313	4.335	6.518	14.83
F10	2.377	4.450	6.678	14.56
F11	2.361	4.519	6.894	17.07
F12	2.181	4.154	7.384	15.07

In this present study, two polymers HPMC K4M and Carbopol 971 were used in formulated HCTZ floating tablets to evaluate whether any change in release pattern due to polymer types. HPMC is a hydrophilic polymer and most widely used for controlled-release drug formulations. The release of drug from HPMC K4M based floating tablets was more than Carbopol based tablets. Drug release decreased with increase of polymer loading as HPMC polymers form viscous gelatinous layer (gel layer) upon exposure to aqueous medium by undergoing rapid hydration and chain relaxation and this gel layer acts as the barrier to release of drug and as a result drug release is prolonged. On the other hand Carbomers are synthetic high-molecular-weight polymers of acrylic acid and they are readily water-swallowable polymers. Carbopol 971 containing tablets showed better controlled release when compared to

HPMC K4M. Formulation containing carbopol 971 also showed decrease of drug release with the increase of amount of polymer.

From the present study, it is clear that T_{25%}, T_{50%} and T_{75%} values were changed due to the change of the amount of HPMC K4M and Carbopol 971 in the floating tablets (Table 6). In all these formulations, the values of T_{50%} and T_{75%} are larger for those formulations which contain larger quantities of HPMC K4M and Carbopol 971. This observation draws an important conclusion that the increase of HPMC K4M and Carbopol 971 content causes the decrease of rate and extent of HCTZ release. In all cases, the increase of the amount of HPMC K4M causes less release of drug in dissolution study which is supported by the values of T_{50%}.




Figure 2. Dissolution release model of HCTZ floating tablets containing (a) HPMC K4M and (b) Carbopol 971.




Figure 3. Effect of polymer concentration and viscosity (HPMC K4M and Carbopol 971) on drug release rate.

Mean Dissolution Time (MDT) value is used to characterize the drug release rate from the dosage form and the retarding efficacy of the polymer. A high value of MDT indicates a long retarding ability and vice-versa. This MDT value was found to be below

for formulation F2 and high for formulation F7 (Table 6). In other words, the formulations containing higher percentage of polymer exhibited a higher value of MDT.

CONCLUSION

From the study, it is possible to conclude that the floating dosage forms enable prolonged and continuous input of the drugs to the upper part of the gastrointestinal tract and improve the bioavailability of medications that are characterized by a narrow absorption window. The study reveals that, the proposed tablet formulations were suitable for direct compression method and the incorporation of HPMC K4M and Carbopol 971 as rate controlling polymer showed the good relation between buoyancy and drug release rate. This provides a good scope for scientists working in this area to effectively use the potential of this drug delivery system for the benefit of mankind.

REFERENCES

- Liu, Q. and Fassihi, R. 2008. Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system. *Int. J. Pharm.* **348**, 27-34.
- Chen, J. and Park, K. 2000. Synthesis of fast-swelling, superporous sucrose hydrogels. *Carbohydr. Polym.* **41**, 259-268.
- Bardonnnet, P., Faivre, V. and Pugh, W. 2006. Gastroretentive dosage forms: overview and special case of *Helicobacter pylori*. *J. Control. Release.* **111**, 1-18.
- Klausner, E.A., Eran, L. and Michael, F. 2003. Expandable gastroretentive dosage forms. *J. Control. Release.* **90**, 143-162.
- Lee, J.W., Park, J.H. and Robinson, J.R. 2000. Bioadhesive-based dosage forms: the next generation. *J. Pharm. Sci.* **89**, 850-866.
- Alexander, S., Juergen, S. and Roland, B. 2006. Drug delivery to the upper small intestine window using gastroretentive technologies. *Curr. Opin. Pharmacol.* **6**, 501-508.
- Whitehead, L., Fell, J.T. and Sharma, H.L. 1998. Floating dosage forms: an *in vivo* study demonstrating prolonged gastric retention. *J. Control. Release.* **55**, 3-12.
- Hardman, J.G., Limbird, L.E. and Gilman, A.G. 2001. *The Pharmacological Basis of Therapeutics*. New York, McGraw Hill. p.774.
- James, W.A. Expandable gastric retention device. 2004, US Patent US2004/0219186A1.
- Shato, H., Miyagawa, Y. and Okabe, T. 1997. Dissolution mechanism of diclofenac sodium from wax matrix granules. *J. Pharm. Sci.* **86**, 929-934.
- Hossain, M.S., Banik, S. and Islam, M.S. 2012. Formulation Design and Characterization of Kollidon SR Based Trimetazidine Dihydrochloride Matrix Tablets. *Ind. J. Pharm. Edu. Res.* **46**, 136-144.
- Rosa, M., Zia, H. and Rhodes, T. 1994. Design and testing in vitro of a bioadhesive and floating drug delivery system for oral application. *Int. J. Pharm.* **105**, 65-70.
- Colombo, P., Bettini, R., Santi, P., Ascentiis, De.A. and Peppas, N.A. 1996. Analysis of the swelling and releasemechanisms from drug delivery systems with emphasis on drug solubility and water transport. *J. Control. Rel.* **39**, 231 - 237.
- Korsmeyer, R.W., Gurny, R. and Peppas, N.A. 1983. Mechanism of solute release from porous hydrophilic polymers. *Int. J. Pharm.* **15**, 25-35.
- Shato, H., Miyagawa, Y. and Okabe, T. 1997. Dissolution mechanism of diclofenac sodium from wax matrix granules. *J. Pharm. Sci.* **86**, 929-934.
- Mockel, J.E. and Lippold, B.C. 1993. Zero-order release from hydrocolloid matrices. *Pharm. Res.* **10**, 1066-1070.
- Ritger, P.L. and Peppas, N.A. 1987. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. *J. Control. Rel.* **5**, 37-42.
- Gupta, A.K. 1994. *Introduction to Pharmaceutics-I*. CBS publishers, Delhi. 3rd edn. pp. 267- 268.